Quoin Pharmaceuticals Ltd.: January 2025 8-K Report Highlights

Based on the provided section of the financial report, here are the key extracted details and insights:

Entity Information:

Entity Name: Quoin Pharmaceuticals Ltd.
CIK (Central Index Key): 0001671502
SEC File Number: 001-37846
Tax ID (EIN): 92-2593104
Address: 42127 Pleasant Forest Court, Ashburn, VA 20148-7349
Phone Number: 703-980-4182

Filing Type:

Filing Form: 8-K (This typically indicates a current report to announce major events that shareholders should know about.)

Filing Date:

Report Date: January 14, 2025

Securities Information:

Type of Shares: American Depositary Shares (ADS), each representing one Ordinary Share.
Ordinary Share Par Value: No par value per share
Ticker Symbol: QNRX
Exchange: NASDAQ

Contextual Information:

Reporting Period: The filing pertains to a specific date, January 14, 2025.
Currency: The financial reporting is in U.S. Dollars (USD).

Insights:

Company Overview: Quoin Pharmaceuticals is positioned as a biotech firm, potentially focusing on pharmaceutical developments, as inferred from the name.
Market Presence: Being listed on NASDAQ indicates a level of maturity and regulatory compliance, which can attract investors.
8-K Filing: The use of an 8-K form suggests that there may be significant information or events disclosed that could impact the company’s stock price or operations.
Share Structure: The distinction between American Depositary Shares and ordinary shares points to the company’s engagement in international markets or investment strategies aimed at U.S. investors.

This summary encapsulates the essential data points and provides an overview of the company’s status as of the filing date. Further analysis would require additional context or details on the specific events disclosed in the 8-K filing.